An evaluation of the FLOWMod system to occlude vena cava blood flow in subjects with acute decompensated heart failure
NCT ID NCT07810335
First seen Sep 09, 2026 · Last updated Sep 09, 2026
Summary
FLOW-HF will assess the impact of intermittent partial occlusion of the SVC and/or IVC, the cardiac filling pressure and the difference of effects between the two occlusion locations (SVC and IVC) using the FlowMod flow modulating device on select parameters in subjects experiencing ADHF (Acute Decompensated Heart Failure)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Male or females between 18 and 85 years of age NYHA Class III-IV heart failure Stage C-D systolic heart failure Clinically indicated for right heart catheterization Volume overload status of the subject confirmed by the presence of at least 1 or more of the following congestion signs or symptoms assessed by physical examination or x-ray: Peripheral edema, rales, jugular venous distension, abdominal distension or evidence of congestion by chest x-ray Subjects with RAP \>10 mmHg Subjects with PCWP \>18 mmHg Subjects with inadequate diuresis defined as total urinary output over the most recent 8 hours prior to enrollment of \<1200 mL while on a stable dose of diuretics Subjects with eGFR \>30mL/min/1.732 Exclusion Criteria: Severe valvular stenosis Severe aortic valve regurgitation Subjects with a contraindication to contrast dye Active myocardial ischemia (MI) or acute coronary syndrome (ACS) ACS or MI within 30 days prior to enrollment Contraindication to unfractionated heparin Unable to provide informed consent Subjects with impaired decision-making capacity Subjects receiving mechanical circulatory support Subjects with history of cardiac transplant Pregnant subjects Right atrial/ventricular thrombus Subjects with inadequate jugular vein access due to prior jugular vein thrombosis or indwelling chronic ports or catheters or presence of vena cava filter Inability to tolerate right heart catheterization Subjects who have a history of major or minor stroke or TIA ≤ 12 months or subjects with a history of stroke \> 12 months who have a residual neurological deficit Hypersensitivity or contraindication to latex Sustained ventricular tachycardia (\>10 beats) within 24 hours and/or ventricular fibrillation within 24 hours Subjects with history of CABG ≤ 3 months Subjects with pacemaker or defibrillator leads placed through the SVC ≤ 3 months prior to procedure Rapid atrial fibrillation (HR\>120 bpm) Systolic blood pressure \< 90 mm Hg Inability to interrupt the anticoagulation treatment Subjects with known coagulopathy or any blood disorders Subjects with life expectancy of \<30 days or known risk for mortality within 90 days Prior carotid interventions (stenting or endarterectomy) Severe carotid disease History of DVT (\<6m or requiring ongoing anticoagulants for either DVT or hypercoagulable state) History of pulmonary embolism SVC/IVC stenosis SVC/IVC diameter not suitable for balloon inflations Subjects receiving hemodialysis or planning to within 30 days Planned LVAD device placement Subject on \>2 inotropes or escalating inotropes during pre-enrollment hospitalization Right ventricular failure based on an RA:PCWP ratio of \>0.8, PAPi\<1.0; or TAPSE\<10 Subjects with Ejection Fraction (EF) of \<15%
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute decompensated heart failure (ADHF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
4 sites in 2 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Ezgu Niyat Medical Clinic
Tashkent, Uzbekistan
-
Republican Specialized Center of Cardiology
Tashkent, Uzbekistan
-
Tbilisi Heart And Vascular Clinic
Tbilisi, Georgia
-
Tbilisi Heart Center
Tbilisi, 0186, Georgia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a diabetes drug clear fluid from lungs in heart failure?
- Bedside blood test may reveal how well heart failure treatment works
- Can a newer heart failure drug protect kidneys better than an older one?
- ER study: does how you give water pills matter for heart failure?
- Could inflatable leg boots help heart failure patients?
- New heart failure drug trial aims to ease breathing and save lives